DOCSLIB.ORG

Actelion Presentation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Actelion Presentation Together we innovate … Strategy Analysis March 2009 Josselin Courselle Rebecca Deprez Julien Maurin Thomas Patard 1 This is an independent study performed by students from the Faculté des Sciences Pharmaceutiques of Lille. The opinions expressed are our own and not necessarily those of Actelion. 2 From ambition … − 1990 : Roche discovered the first ENTDOANHELIN RECEPTOR TAGONIST − 1996 : Roche drops clinical trials on bosentan (liver toxicity). − 1997: Founding Actelion. (Allschwil, Switzerland) JP Clozel M Clozel A Muller W Fischli T Widmann CEO VP Drug Discovery, Chairman Board VP Drug Discovery, Former CEO Pharmacology Former CFO Biology Preclinical Dev 3 … to realization 10 years on − 20 countries worldwide − 1949 employees − 2000 : IPO Swiss New Market (256Mio CHF) − In the top-15 biopharmaceutical companies − 2008 : Entry into the SwissMarketIndex , Best performing stock ! Sales Marketing Development 4 3 Marketed products Zavesca® (miglustat) Type 1 Gaucher’s disease Ventavis® (iloprost) Inhaled prostacyclin for PAH therapy Tracleer® (bosentan) Oral dual endothelin receptor antagonist « Entan » For PAH & Digital Ulcers 5 Actelion : A strong communication on Pulmonary Arterial Hypertension, Endothelin,« Entans » PAH_info.com Endothelin.org Owns visual and verbal nomenclature of an entirely new class of compounds 6 Actelion in Mid-2003 Acquisition Partnership Veletri tezosentan In-Licencing Reward Risk Generics Specialty Orphan drugs Hospital drugs GP products Pharmaceuticals Actelion : A Clinical Developement Company 7 2003-2004: moving upward the DD pipeline Sept-2003 :Axovan acquisition • Phase II clazosentan GPCR • Numerous pre-clinical projects • Chemistry platform • GPCR platform Actelion : A Drug discovery Company 8 2003-2008 : Niche extension PAH & CardioVascular diseases Acquisition PGI2 agonist Partnership In-Licencing Pivlaz Reward Macitentan Clazosentan Risk Veletri tezosentan Generics Specialty Orphan drugs Hospital drugs GP products Pharmaceuticals 9 2003-2008 : Moving towards GP market Acquisition S1P1 Agonist Partnership Orexin Antagonist In-Licencing CRTH2 Antagonist Reward Risk Renin Inhibitor Generics Specialty Orphan drugs Hospital drugs GP products Pharmaceuticals 10 Major therapeutic areas & Marketed Products − Pulmonary Arterial Hypertension −Gaucher’s disease 11 What is PAH? -Sustained elevation of pulmonary vascular resistance : >25 mmHg (at rest) >30 mmHg (while exercising) right ventricular failure and premature death (median survival 2.8 y) -Small pulmonary arteries obstruction due to Vasoconstriction Thrombosis Smooth muscle and endothelial cell proliferation 12 WHO functionnal classes Class I PAH but without limitation of physical activity. Slight limitation of unsual physical activity : dyspnoea or Class II fatigue, chest pain or near syncope Comfortable at rest Marked limitation of ordinary physical activity. Class III Comfortable at rest. Inability to carry out any physical activity without Class IV symptoms. Signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest mean age of diagnosis: 36 years1 prevalence of 30-50 cases per million2 1: Sitbon O et al. Am J Resp Crit Care Med 2008 ; 2: Peacock AJ. BMJ 2003 13 Why does it develop? − Reduced production of vasodilators – Prostacyclin – NO − Increased production of vasoactive compounds – Endothelin (ET) 14 PAH therapy & Actelion portfolio 15 PGI2 pathway : Competitors ® ® Flolan (epoprostenol: PGI2) Remodulin (treprostinil) Natural prostacyclin Synthetic analogue Short half-life Preferentially given subcutaneously Intraveinous perfusion (small infusion pump) Low impact on quality of life and Pain and discomfort (85% of patients) mortality 75,000 $/year 45,000 $/year 16 Ventavis® (Iloprost) for PAH GPCR PGI2 receptor agonist 2007: CoTherix acquisition 17 Ventavis®, freedom from iv prostacyclins Inhaled formulation of iloprost ↑ stability and ↑ half-life vs natural PGI2 Approved for PAH Class III or IV Cost: 3100€ / year The only inhaled PAH therapy on the US market 18 Ventavis®, contributing to growth − Developed by Schering − 2004 :Approval & Licenced to CoTherix in US − 2007 :Acquisition of CoTherix Bayer Schering Pharma sales in EU & other countries; Actelion in US − 2008 : Sales reach CHF 94.6 m 34% increment 19 Ventavis® : Improve access to treatment I-neb Adaptative Aerosol Delivery System Pulmonary drug delivery device Battery powered Adaptive Aerosol Delivery (AAD®) technology: −Constant amount of drug is inhaled −No waste Ann Pharmacother. 2005 Jul-Aug;39(7-8):1265-74. Prodose AAD Inhaled iloprost in pulmonary arterial hypertension. Baker SE, Hockman RH. 20 Tracleer® (bosentan) for PAH GPCR Mixed ETA/ETB entan 1st in class 21 2000: in-licenced from Roche ET mediated effects in PAH British Journal of Pharmacology (2008) 153, 1105–1119 22 Bosentan Tracleer® - 2002 : PAH class III & IV - 2008 : PAH class II (EARLY) - 2008 : Digital Ulcers (PAH with connective tissue diseases like systemic sclerodermia) - Sales : CHF 1.2 b ; +17%; constant growth 23 Entans competition ICOS/Encysive/Pfizer Launched Myogen/Gilead/GSK Launched −Ambrisentan (Letairis® Volibris ® ) 2008 : $112.9 million (US); EU launched −Sitaxsentan (Thelin ® ) acquired by Pfizer in 2008 Gilead Phase III Updated from Nature Reviews Drug Discovery 986 | 2002 | VOLUME1 24 Other PAH competitors in NO pathway − Sildenafil (Revatio ® Pfizer) PDE5 inhibitor (03/2005). − Riociguat (Bayer Schering Pharma) soluble guanylate cyclase (sGC) stimulators. Phase III 25 Miglustat (ZavescaTM) Targeting Genetic disorders 2002: in licenced from OGS / then Celltech 26 Type 1 Gaucher : A bone disease − Inherited autosomal recessive disorder − Reduced activity of lysosomal ß-glucocerebrosidase − Accumulation of glucosylceramide − Necrosis of bone marrow infiltrated with Gaucher cells − Bone pain, osteonecrosis due to abnormal remodeling 27 Type 1 Gaucher : Treatment − Enzyme replacement − Substrate Reduction therapy (inb. Glucosylceramide synthase) − Chemical chaperone Glucosylceramide Defective Enzyme- glucosylceramide ß-glucocerebrosidase replacement synthase therapy (ERT) Substrate reduction CEREZYME® therapy Ceramide 60 IU/kg/2 weeks ~86 140 - 430 700 € /y Chemical chaperones to reactivate defective enzymes 3*100 mg/day ~91 881 € /y Future Lipidol. 2008 June ; 3(3): 273–300. NATURE REVIEWS | MOLECULAR CELL BIOLOGY V5 | JULY 2004 | 554 NATURE REVIEWS | CANCER V4 | AUGUST 2004 | 604 28 Miglustat sales +20% 29 Niemann-Pick type C disease − Very rare − Reduced activity of lysosomal sphingomyelinase − Accumulation of sphingomyelin − Severe SNC disabilities − Zavesca® Approved in 2008 as a sphingomyeline synthase inhibitor Substrate reduction therapy 30 Broad Clinical Portfolio 31 Life cycle management & current drug families Miglustat Iloprost & other PGI2r agonists Entans 32 Zavesca® in Cystic Fibrosis − Autosomal recessive genetic disorder − Progressive lung & pancreas dysfunction − Caused by defected CFTR chloride channel −Norez C., Noel S., Wilke M., Bijvelds M., Jorna H., Melin P., DeJonge H. and Becq F. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett. 508, 2081-86; 2006. 33 Zavesca® in Cystic Fibrosis Chemical chaperones to reactivate defective enzymes − Acts as a chemical chaperone of the CFTR (del508) − Phase IIa results expected Q2-2009 −Norez C., Noel S., Wilke M., Bijvelds M., Jorna H., Melin P., DeJonge H. and Becq F. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett. 508, 2081-86; 2006. −Antigny et al, Cell Calcium, 43, 175-183 2008 34 PGI2 agonists :Improve patient access to treatment Q2 2009 – PROWESS 15 New device to ↓ inhalation time and ↑ patient compliance Study design: 64 patients, crossover study 35 PGI2 agonists : New combinations ? 2006 :phase II/III STEP Efficacy and added benefit of using Ventavis® in patients with PAH already undergoing treatment with bosentan, or sildenafil Mc Laughlin et al., AJRCCM, 2006 Ghofrani et al., JACC, 2003 36 GPCR Improve patient access to treatment : PGI2 agonists in a pill ? − Discovered by Nippon Shinyaku − 2008: Actelion outside Japan & co-development & commercialization in Japan − First-in-class , Non-prostanoid PGI2 receptor agonist − Pro-drug offers protection to gastro-intestinal tract 37 ACT-293987: current status Results of phase I Good safety profile Linear PK after single oral dose Half-life supports twice-a-day oral dosing No accumulation after multiple dosing 2008 : A phase IIa study in PAH Objective: evaluate acute hemodynamic effects and tolerability of up-titration to 800μg bid Results are expected in Q3 2009 −Kuwano et al (2008). J Pharmacol Exp Ther 326: 691-699. 38 Bosentan : Extension of Indications 2002 Chronic Thrombo Embolic Pulmonary Hypertension 2007 2008 + Sildenafil 39 Bosentan in IPF (Idiopathic Pulmonary Fibrosis ) Ph.III − Orphan disease − Easily diagnosed (unlike PAH) − Death in 3-years − Bosentan normalizes cells with fibers − Results expected in Q2-2009 − If Bosentan goes in IPF, Fast track status and double revenue in 2 years King T.E. et al. High-resolution computed tomography (HRCT) features correlate with response to bosentan in idiopathic pulmonary fibrosis (IPF): the BUILD 1 study [abstract]. Am J Respir Crit Care Med. 175:A567; 2007. 40 Macitentan in PAH Ph.III − 100 times more potent than bosentan − Mixte ETA/ETB − Directed towards tissues to avoid vascular effects − SERAPHIN study − Expected results
Load more

Recommended publications
  • 204569Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204569Orig1s000 MEDICAL REVIEW(S) Cross Discipline Team Leader Review 3. CMC/Device Dr. Khairuzzaman found the drug product portion of the NDA to be acceptable, and without need for phase 4 commitments. Dr. Sapru’s review stated that with the exception of a pending issue concerning the control of potential genotoxic impurity (b) (4) the NDA was approvable in terms of drug substance. Dr. Suarez found that the NDA was acceptable from a biopharmaceutics perspective. The Office of Compliance issuance of an acceptable recommendation for drug substance manufacturing and testing facilities was pending at the time of this review. 4. Nonclinical Pharmacology/Toxicology Dr. Richard Siarey completed the primary nonclinical review, and Dr. Lois Freed completed a supervisory memo. Dr. Siarey’s overall conclusion was that from a nonclinical perspective, approval of the suvorexant NDA was recommended. However, he found evidence that catapelxy was observed in dogs exposed to MK-4305 (suvorexant) near Tmax, although he concluded that additional information could have been gained by studying the drug in an experimental model that has been used for diagnosing cataplexy in dogs. Dr. Siarey suggested that since cataplexy occurred in dogs near Tmax, a time at which if used for insomnia patients would ordinarily be in bed, safety concern for humans was reduced. Dr. Siarey also found that the neurobehavioral assessment in the pre- and post-natal developmental study was not complete, as the passive avoidance tests was performed too early in development, while learning/acquisition tests and retention/memory tests were not conducted.
    [Show full text]
  • Anti-Infectives Industry Over the Next 5 Years and Beyond
    Bridging the innovation gap... New Drug Futures: Products that could change the pharma market to 2013 and beyond Over 70 pipeline prospects This new major and insightful 450 page in 8 major therapy areas analysis evaluates, compares and contrasts the are analysed in this report prospects for the development compounds that could revolutionise the pharmaceutical Anti-infectives industry over the next 5 years and beyond. Cardiovascular CNS The report provides: Gastrointestinal Detailed background and market context for Metabolic each therapy area covered: Musculoskeletal Addressable patient population Oncology Current treatments Sales drivers Respiratory Sales breakers Future treatments Market dynamics – winners and losers Key drug launches by 2013 Unique sales forecasts by major product to 2013 Over 70 key products assessed Unique evaluation scores for key areas such as novelty of mechanism, clinical data and competition Critical and detailed appraisal of each product‟s research and development Extensive pipeline listings, putting the profiled products into their competitive context The search – and need – for new products has never been greater and what’s in the development pipeline has never generated more interest. That is why this analysis is so important! GLOBAL PHARMA MARKET IN CONTEXT THE Are there too many prophets of doom ready to write-off the research-based pharma industry in the future? Too few novel There is plenty on which to base such anxiety. The research-based industry products and an must achieve a fair price in the face of greater cost control, while the aggressive generic burden of regulation is setting the bar high for successful product sector are taking introduction.
    [Show full text]
  • The Dual Orexin Receptor Antagonist TCS1102 Does Not Affect Reinstatement of Nicotine- Seeking
    RESEARCH ARTICLE The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine- seeking Shaun Yon-Seng Khoo, Gavan P. McNally, Kelly J. Clemens* School of Psychology, University of New South Wales, Sydney, Australia * [email protected] a1111111111 a1111111111 a1111111111 Abstract a1111111111 a1111111111 The orexin/hypocretin system is important for appetitive motivation towards multiple drugs of abuse, including nicotine. Both OX1 and OX2 receptors individually have been shown to influence nicotine self-administration and reinstatement. Due to the increasing clinical use of dual orexin receptor antagonists in the treatment of disorders such as insomnia, we OPEN ACCESS examined whether a dual orexin receptor antagonist may also be effective in reducing nico- Citation: Khoo SY-S, McNally GP, Clemens KJ tine seeking. We tested the effect of intracerebroventricular (i.c.v.) administration of the (2017) The dual orexin receptor antagonist potent and selective dual orexin receptor antagonist TCS1102 on orexin-A-induced food TCS1102 does not affect reinstatement of nicotine- self-administration, nicotine self-administration and reinstatement of nicotine-seeking in seeking. PLoS ONE 12(3): e0173967. https://doi. org/10.1371/journal.pone.0173967 rats. Our results show that 30 μg of TCS1102 i.c.v. abolishes orexin-A-induced increases in food self-administration but does not reduce nicotine self-administration. Neither i.c.v. 10 μg Editor: Judith Homberg, Radboud University Medical Centre, NETHERLANDS nor 30 μg of TCS1102 reduced compound reinstatement after short-term (15 days) self- administration nicotine, but 30 μg transiently reduced cue/nicotine compound reinstatement Received: November 24, 2016 after chronic self-administration (29 days).
    [Show full text]
  • Annual HFHS Publications List 2017 This Bibliography Aims to Recognize
    Annual HFHS Publications List 2017 This bibliography aims to recognize the scholarly activity and provide ease of access to journal articles, meeting abstracts, book chapters, books and other works published by Henry Ford Health System personnel. Searches were conducted in PubMed, Embase, Web of Science, and Google Scholar during 2017, and then imported into EndNote for formatting. The searches captured over 1,500 unique publications from Henry Ford Health System authors for 2017. Click the “Full Text” link to view the articles to which Sladen Library provides access. If the full-text of the article is not available, you may request it through ILLiad by clicking on the “Article Request Form,” or by calling us at 313-916-2550. If you would like to be added to the monthly email distribution list to automatically receive a PDF of this bibliography in your inbox, or you have any questions or comments, please contact Angela Cabrera at [email protected]. Administration Omar J, Heidemann DL, Blum-Alexandar B, Uju-Eke C, Alam Z, Willens DE, and Wisdom K. Fresh prescription: Improving nutrition education and access to fresh produce in Detroit J Gen Intern Med 2017; 32(2):S752. PMID: Not assigned. Abstract Administration Smith KL, Fedel P, and Heitman J. Incapacitated surrogates: A new and increasing dilemma in hospital care J Clin Ethics 2017; 28(4):279-289. PMID: 29257763. Article Request Form Allergy Brown KR, Krouse RZ, Calatroni A, Visness CM, Sivaprasad U, Kercsmar CM, Matsui EC, West JB, Makhija MM, Gill MA, Kim H, Kattan M, Pillai D, Gern JE, Busse WW, Togias A, Liu AH, and Khurana Hershey GK.
    [Show full text]
  • 2017 Research Annual Report Table of Contents Summaries of 2017
    2017 RESEARCH ANNUAL REPORT TABLE OF CONTENTS SUMMARIES OF 2017 NATIONAL INSTITUTES OF HEALTH AND OTHER FEDERAL GRANTS AWARDED TO HFHS PART I – INTERNAL MEDICINE DEPARTMENT_________________________________ ALLERGY AND IMMUNOLOGY ................................................................................................. 1 CARDIOLOGY/CARDIOVASCULAR RESEARCH…………………………………………….1 ENDOCRINOLOGY AND METABOLISM .................................................................................. 2 GASTROENTEROLOGY ............................................................................................................. .3 HEMATOLOGY/ONCOLOGY…………………………………………………………………...4 HYPERTENSION AND VASCULAR RESEARCH……………………………………………...5 INFECTIOUS DISEASE…………………………………………………………………………..9 PULMONARY……………………………………………………………………………………10 SLEEP MEDICINE ....................................................................................................................... 11 GENERAL INTERNAL MEDICINE…………………………………………………………….13 PART II – ALL OTHER CLINICAL DEPARTMENTS_______________________________ DERMATOLOGY ........................................................................................................................ 14 NEUROLOGY .............................................................................................................................. 15 NEUROSURGERY……………………………………………………………………………….23 ORTHOPAEDICS/BONE & JOINT……………………………………………………………..24 PATHOLOGY ..............................................................................................................................
    [Show full text]
  • Study Protocol
    Confidential Page 1 Protocol No. Everolimus Investigator-initiated Protocol Template RAD001 (Everolimus) Clinical evaluation of everolimus (a rapamycin analog) in restoring salivary gland function to patients treated with radiotherapy for head and neck cancer CRAD001XUS274T Authors: Panayiotis Savvides, MD PhD MPH (Principal Investigator) Kirsten Limesand, PhD (co-Investigator) Denise Roe, DrPH (co-Investigator) Sun Yi, MD (co-Investigator) Julie Bauman, MD (co-Investigator) Daruka Mahadevan, MD PhD (co-Investigator) Version number: 1.2 Release date 06/22/2018 Referenced Investigator Brochure 15, release date 27-April-2016 Edition IRB NUMBER: PHXB-17-0072-70-15 IRB APPROVAL DATE: 07/03/2018 Confidential Page 2 Protocol No. Table of contents Table of contents..................................................................................................................2 List of figures.......................................................................................................................3 List of tables.........................................................................................................................3 List of abbreviations ............................................................................................................4 Glossary of terms.................................................................................................................6 Schema.................................................................................................................................8 1
    [Show full text]
  • Understanding Peptide Binding in Class a G Protein-Coupled Receptors
    Molecular Pharmacology Fast Forward. Published on July 10, 2019 as DOI: 10.1124/mol.119.115915 This article has not been copyedited and formatted. The final version may differ from this version. MOL# 115915 Understanding peptide binding in Class A G protein-coupled receptors Irina G. Tikhonova, Veronique Gigoux, Daniel Fourmy School of Pharmacy, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 7BL, Northern Ireland, United Kingdom, (I.G.T.) INSERM ERL1226-Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F- 31432 Toulouse, France. (V.G., D.F.) Downloaded from molpharm.aspetjournals.org Keywords: peptides, peptide GPCRs, peptide binding at ASPET Journals on September 30, 2021 1 Molecular Pharmacology Fast Forward. Published on July 10, 2019 as DOI: 10.1124/mol.119.115915 This article has not been copyedited and formatted. The final version may differ from this version. MOL# 115915 Running title page: Peptide Class A GPCRs Corresponding author: Irina G. Tikhonova School of Pharmacy, Medical Biology Centre, 97 Lisburn Road, Queen’s University Belfast, Belfast BT9 7BL, Northern Ireland, United Kingdom Email: [email protected] Tel: +44 (0)28 9097 2202 Downloaded from Number of text pages: 10 Number of figures: 3 molpharm.aspetjournals.org Number of references: 118 Number of tables: 2 Words in Abstract: 163 Words in Introduction: 503 Words in Concluding Remarks: 661 at ASPET Journals on September 30, 2021 ABBREVIATIONS: AT1,
    [Show full text]
  • Annual Report 2007 in Detail
    Annual Report 2007 In Detail WorldReginfo - 954f6161-6bac-48a4-873f-6ee9f4f1d49c Content WorldReginfo - 954f6161-6bac-48a4-873f-6ee9f4f1d49c 01 Marketed Products 04 Summary of Achievements 05 Tracleer® 06 Ventavis® 08 Zavesca® 08 02 Research & Development 10 Drug Discovery 11 Drug Discovery Platforms 11 Therapeutic Areas 12 Clinical Development 18 03 Our Strategy 27 04 Business Development 29 05 Financial Report 32 Corporate Governance 37 Consolidated Financial Statements 49 Holding Company Statements 78 03 WorldReginfo - 954f6161-6bac-48a4-873f-6ee9f4f1d49c 01 Marketed Products WorldReginfo - 954f6161-6bac-48a4-873f-6ee9f4f1d49c Summary of achievements Actelion’s strong commitment to expand Tracleer® into new indications is demonstrated by the comprehensive clini- Actelion continued its strong performance in 2007 and further cal trial program, including the COMPASS trials (combina- built its leadership position in pulmonary arterial hypertension tion therapy), BUILD 3 (idiopathic pulmonary fibrosis) and (PAH) with Tracleer® (bosentan) sales of CHF 1,18 billion, a FUTURE (pediatric indication). growth of 31% compared to the previous year (+32% in lo- cal currencies). This strong performance was seen in all re- Several marketing and life cycle activities were initiated for gions worldwide, including the United States, Europe, and Ventavis® in 2007 to enhance its profile and set it up for con- Japan in particular. It was also the first full year of marketing tinued success in 2008. Ventavis® (iloprost) after the acquisition of CoTherix in the United States. In an increasingly competitive PAH market, Zavesca® (miglustat), Actelion’s second global brand, gener- Ventavis® was able to contribute CHF 78.2 million to our PAH ated sales of CHF 35.3 million, a growth of 39% compared franchise revenues.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
    INN Working Document 18.435 31/05/2018 Addendum1 to "The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances" WHO/EMP/RHT/TSN/2013.1 Programme on International Nonproprietary Names (INN) Technologies Standards and Norms (TSN) Regulation of Medicines and other health technologies (RHT) World Health Organization, Geneva © World Health Organization 2018 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme. This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization. Addendum1 to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2013.1 1 This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" 2013. ------------------------------------------------------------------------------------------------------------ -apt- aptamers, classical and mirror ones (a) avacincaptad pegol (113), egaptivon pegol (111), emapticap pegol (108), lexaptepid pegol (108), olaptesed pegol (109), pegaptanib (88) (b) -vaptan stem: balovaptan (116), conivaptan
    [Show full text]
  • A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
    Clinical Study Protocol AstraZeneca AZD1775 - D6010C00004 Version 10, 05 September 2018 Clinical Study Protocol Drug Substance AZD1775 Study Code D6010C00004 Version 10 Date 05 September 2018 A Multicentre Phase II Study of AZD1775 plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Sponsor: AstraZeneca AB, 151 85 Södertälje, Sweden. EudraCT: 2015-000886-30 CONFIDENTIAL AND PROPRIETARY 1 of 153 Clinical Study Protocol AstraZeneca AZD1775 - D6010C00004 Version 10, 05 September 2018 VERSION HISTORY Version 10.0, 05 September 2018 (Amendment 9) Changes to the protocol are summarised below: ! Specified that patients still receiving AZD1775 after the primary data cut-off will have a Final Protocol Visit (FPV) occurring at their next scheduled visit focused on capturing safety information. Following the FPV, patients may continue to receive treatment with AZD1775 ± chemotherapy as deemed appropriate by the Investigator (see Table 2, footnote ‘bb’, Table 3, footnote ‘cc’, and Section 4.4). The end-of-study treatment visit is not required for patients continuing treatment after the FPV. ! Amended Section 5.6 to add clarification about optional tumour biopsies. ! Clarified that blood samples and optional tumour biopsies for exploratory biomarker research will be collected at treatment discontinuation due to disease progression for subjects that continue taking AZD1775 ± chemotherapy after the FPV (see Section 5.6). ! Clarified how SAEs will be reported after the FPV (see Section 6.4.1 and Section 6.5). ! Clarified that after the FPV pregnancies will be monitored while patients are on treatment and for 30 days after their final dose of AZD1775 ±chemotherapy (Section 6.7).
    [Show full text]
  • Nonpublication of Trial Results for New Neurological Drugs: a Systematic Review
    Nonpublication of Trial Results for New Neurological Drugs: A Systematic Review NOTE: This is an earlier version of the manuscript published in Annals of Neurology 2017. It contains information and data that editors/referees asked us to remove as a condition for acceptance. We strongly disagreed and therefore present those data in this version. Amanda K Hakala1, BSc, Dean Fergusson2, PhD, Jonathan Kimmelman1*, PhD 1 Studies of Translation, Ethics, and Medicine (STREAM), Biomedical Ethics Unit, McGill University, H3A 1X1, Montreal, Canada 2 Centre for Practice Changing Research, Ottawa Hospital Research Institute, University of Ottawa, K1H 8L6, Ottawa, Canada Corresponding author: Jonathan Kimmelman [email protected] (514) 398-3306 Abstract word count: 236 Introduction word count: 302 Discussion word count: 885 Total manuscript body word count: 2996 Number of figures: 3 Number of tables: 3 1 ABSTRACT Objective: To evaluate nonpublication rates among trials of new successful and unsuccessful neurological drugs. Methods: Our ‘licensed’ drug cohort consisted of all novel drugs receiving FDA licensure 2005 to 2012 inclusive in seven neurological disorders. Our cohort of ‘stalled’ drugs included all experimental agents tested in the same domains that had at least one completed phase III trial in the same timeframe but failed to receive FDA approval. Trials of these drugs were included in our sample if their primary outcome collection occurred before October 1, 2010. We determined the publication status of eligible trials using searches of clinicaltrials.gov, Google Scholar, PubMed, Embase, sponsor websites, and direct electronic query of trial contacts and sponsors. The primary outcome was journal publication (or results reporting in other media).
    [Show full text]
  • WO 2017/151816 Al 8 September 2017 (08.09.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/151816 Al 8 September 2017 (08.09.2017) P O P C T (51) International Patent Classification: Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, C07D 495/04 (2006.01) A61P 3/00 (2006.01) California 94404 (US). YANG, Xiaowei; c/o Gilead A61K 31/519 (2006.01) A61P 3/06 (2006.01) Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). (21) International Application Number: PCT/US20 17/020271 (74) Agents: TANNER, Lorna L. et al; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, (22) Date: International Filing California 94301-1479 (US). 1 March 2017 (01 .03.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (30) Priority Data: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 62/302,755 2 March 2016 (02.03.2016) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 62/303,237 3 March 2016 (03.03.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: GILEAD APOLLO, LLC [US/US]; 333 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Lakeside Drive, Foster City, California 94404 (US).
    [Show full text]